Skip to main content

HARVARD BIOSCIENCE INC

For the period ended Jun 30, 2024. Filed Aug 8, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 8, 2024

HBIO$9.09+8.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 5. Other Information

On May 13, 2024, Bertrand Loy, amember of our Board of Directors, adopted a trading plan intended tosatisfy the affirmative defense available under Rule 10b5-1(c) (the “Trading Plan”) in connection with the exercise of options to purchase shares of our common stock expiring on November 13, 2024 and the sale of the underlying shares. The maximum number of shares of our common stock that may be sold under the Trading Plan is 55,300 shares.

The description of the August 2024 Amendment to the Credit Agreement included in Note 8 to the Condensed Consolidated Financial Statements (Unaudited) included in Part I, Item 1 of this quarterly report is incorporated herein by reference. The foregoing description of the August 2024 Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the August 2024 Amendment, which is filed as Exhibit 10.1 to this quarterly report.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.